Literature DB >> 26229395

Alcohol liver disease: A review of current therapeutic approaches to achieve long-term abstinence.

María Luisa Gutiérrez García1, Sara Blasco-Algora1, Conrado M Fernández-Rodríguez1.   

Abstract

Harmful alcohol drinking may lead to significant damage on any organ or system of the body. Alcoholic liver disease (ALD) is the most prevalent cause of advanced liver disease in Europe. In ALD, only alcohol abstinence was associated with a better long-term survival. Therefore, current effective therapeutic strategy should be oriented towards achieving alcohol abstinence or a significant reduction in alcohol consumption. Screening all primary care patients to detect those cases with alcohol abuse has been proposed as population-wide preventive intervention in primary care. It has been suggested that in patients with mild alcohol use disorder the best approach is brief intervention in the primary care setting with the ultimate goal being abstinence, whereas patients with moderate-to-severe alcohol use disorder must be referred to specialized care where detoxification and medical treatment of alcohol dependence must be undertaken.

Entities:  

Keywords:  Alcohol abstinence; Alcohol dependence; Alcohol use disorders; Alcohol withdrawal syndrome; Alcoholic liver disease

Mesh:

Substances:

Year:  2015        PMID: 26229395      PMCID: PMC4515834          DOI: 10.3748/wjg.v21.i28.8516

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  101 in total

1.  Supplementary thiamine is still important in alcohol dependence.

Authors:  Ellen Rees; Linda R Gowing
Journal:  Alcohol Alcohol       Date:  2012-11-16       Impact factor: 2.826

2.  Validation of a single screening question for problem drinking.

Authors:  R Williams; D C Vinson
Journal:  J Fam Pract       Date:  2001-04       Impact factor: 0.493

3.  Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.

Authors:  Karl Mann; Anna Bladström; Lars Torup; Antoni Gual; Wim van den Brink
Journal:  Biol Psychiatry       Date:  2012-12-11       Impact factor: 13.382

4.  AUDIT-C scores as a scaled marker of mean daily drinking, alcohol use disorder severity, and probability of alcohol dependence in a U.S. general population sample of drinkers.

Authors:  Anna D Rubinsky; Deborah A Dawson; Emily C Williams; Daniel R Kivlahan; Katharine A Bradley
Journal:  Alcohol Clin Exp Res       Date:  2013-04-23       Impact factor: 3.455

5.  Propofol for benzodiazepine-refractory alcohol withdrawal in a non-mechanically ventilated patient.

Authors:  Darrel W Hughes; Elizabeth Vanwert; Lauren Lepori; Bruce D Adams
Journal:  Am J Emerg Med       Date:  2013-09-26       Impact factor: 2.469

6.  Screening for alcohol problems in primary care: a systematic review.

Authors:  D A Fiellin; M C Reid; P G O'Connor
Journal:  Arch Intern Med       Date:  2000-07-10

7.  Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial.

Authors:  B A Johnson; J D Roache; M A Javors; C C DiClemente; C R Cloninger; T J Prihoda; P S Bordnick; N Ait-Daoud; J Hensler
Journal:  JAMA       Date:  2000 Aug 23-30       Impact factor: 56.272

Review 8.  Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?

Authors:  Natalya C Maisel; Janet C Blodgett; Paula L Wilbourne; Keith Humphreys; John W Finney
Journal:  Addiction       Date:  2012-10-17       Impact factor: 6.526

Review 9.  Nutrition in alcoholic liver disease.

Authors:  Ashwani K Singal; Michael R Charlton
Journal:  Clin Liver Dis       Date:  2012-11       Impact factor: 6.126

Review 10.  Multidisciplinary approach to a Marfan syndrome patient with emphasis on cardiovascular complications.

Authors:  Petr Santavy
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2013-03-25       Impact factor: 1.245

View more
  1 in total

1.  Inhibition of spleen tyrosine kinase activation ameliorates inflammation, cell death, and steatosis in alcoholic liver disease.

Authors:  Terence N Bukong; Arvin Iracheta-Vellve; Banishree Saha; Aditya Ambade; Abhishek Satishchandran; Benedek Gyongyosi; Patrick Lowe; Donna Catalano; Karen Kodys; Gyongyi Szabo
Journal:  Hepatology       Date:  2016-07-22       Impact factor: 17.425

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.